Active delivery of Zinc Fingers for in vivo enhancement of gene regulation

Reference number 10430a

Sectors: Biotechnology

Industries: Therapeutics

A universal method to enhance control of gene expression in vivo with artificial gene-regulatory transcription factors (TFs).

Summary

We have developed a universal method to enhance control of gene expression in vivo with artificial gene-regulatory transcription factors (TFs). In recent years, there are many examples of designer gene-specific TFs being used to up- or down-regulate target disease genes; the new method promises a significant increase the control of somatic gene expression. The key concept in this example is active delivery of zinc finger peptides (ZFs) by active gene expression, secretion and cell-penetration of designer transcription factors (TFs) such as ZFs. This is demonstrated in cells and is applied in vivo, for example in mouse or humans, using AAV-secretion/penetration ZF constructs.

Technology

The present invention provides new zinc finger peptides and encoding nucleic acid molecules that can be used for the modulation of gene expression in vitro and/or in vivo. The new zinc finger peptides of the invention may be particularly useful in the modulation of target genes associated with expanded GGGGCC hexanucleotide repeats or CGG trinucleotide repeats, and more specifically the targeted repression of such genes.

Applications

Current ZFP therapies are working well for months on end but the expression levels at 6 months and beyond are lower than after initial injection. Typically, only about 25-30% of whole-brain gene targets are repressed beyond 6 months, with standard constructs. Our Active delivery constructs will improve this situation by continuing ‘drip-feeding’ secreted cell-penetrating factors to bystander cells in the brain and other tissues by exploiting ZFs’ intrinsic cell penetrating properties. These cell-penetration properties have not been coupled before to secretion in vivo, nor delivery with AAVs, and this is what is unique about this active delivery concept.

Benefits

  • This invention provides new zinc finger peptides and encoding nucleic acid molecules that can be used for the modulation of gene expression in vitro and/or in vivo.
  • This invention has therapeutic applications for clinical diseases where altered expression of genes is a key part of the disease aetiology

Intellectual Property

This technology is subject of a Priority patent application.

Inventor

Professor Mark Isalan

Professor of Synthetic Biology
Faculty of Natural Sciences, Department of Life Sciences

Visit personal site

Contact us about this technology

Contact

Dr Stuart Sims

Industry Partnerships and Commercialisation Executive, Natural Sciences

Dr Stuart Sims is Industry Partnerships and Commercialisation Executive in the Faculty of Natural Sciences at Imperial College London

Contact Stuart

s.sims@imperial.ac.uk

Related technologies

A cytokine for wound healing and scar reduction

A cytokine for wound healing and scar reduction

A cytokine that promotes wound healing by accelerating re-epithelialization of the wound bed faster than FDA approved products. The treatment also has a potential to minimise scarring after injury. Find out more

A novel targeted drug delivery system

A novel targeted drug delivery system

A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics Find out more

Active delivery of Zinc Fingers for in vivo enhancement of gene regulation

Active delivery of Zinc Fingers for in vivo enhancement of gene regulation

A universal method to enhance control of gene expression in vivo with artificial gene-regulatory transcription factors (TFs). Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...